INmune Bio Inc. (NASDAQ: INMB) is “One to Watch”
INmune Bio’s IPO closed February 1, 2019, with NASDAQ Capital Markets listing on February 4, 2019 Public clinical-stage immunology company with programs in oncology and neurodegenerative disease INmune Bio targets large markets with unsolved problems such as resistance to checkpoint inhibitor therapy, a fast-growing oncology market segment; MRD, the cause of cancer relapse; and neuroinflammation as a cause of Alzheimer’s disease Receiver of “Part the Cloud” $1 million grant awarded by Alzheimer’s Association Experienced leadership with extensive experience in the targeted fields of clinical research and drug development Intellectual property with multiple filings in process for INB03/XPro1595 and INKmune Insider…
